Skip to content
Screener

Ultragenyx Pharmaceutical RARE Other income, net (Note 6)

Other income, net (Note 6) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$987K+868%
Arrowhead Research logo
Arrowhead ResearchARWR
-$1.61M-467%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$8.16M-39.8%
Moderna logo
ModernaMRNA
-$19M-338%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-$31K-338%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.55B-5.8%
P/S3.6×-0.9×

Profitability

See full
Gross margin97.2%
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333233
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss from operations(75)(108)(244)(251)
Interest income561113
Non-cash interest expense on liabilities for sales of future royalties(22)(14)(43)(28)
Other income1212
Loss before income taxes(91)(114)(275)(264)
Provision for income taxes(1)(1)(2)(2)
Net loss$(92)$(115)$(277)$(266)
Net loss per share, basic and diluted$(0.90)$(1.17)$(2.73)$(2.73)

Item 1. Financial Statements

FAQ

What is Ultragenyx Pharmaceutical's other income, net (note 6)?
Ultragenyx Pharmaceutical (RARE) reported other income, net (note 6) of $1M in Q2 2026.
How has Ultragenyx Pharmaceutical's other income, net (note 6) changed year-over-year?
Ultragenyx Pharmaceutical's other income, net (note 6) decreased by 50.0% year-over-year, from $2M to $1M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Ultragenyx Pharmaceutical's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude